Catalent Bolsters End-to-End CDMO Services for Autologous & Allogeneic Cell Therapies, Including iPSC Center of Excellence

August 2, 2026

Catalent USA

Overview

Catalent is enhancing its end-to-end CDMO manufacturing support and process development services for both autologous and allogeneic cell therapies, covering CAR-T, TCR, TIL, NK cells, and iPSC- and MSC-derived treatments. Its Princeton site’s multi-product segregation suites employ closed-system processing to minimize cross-contamination risk and support cGMP compliance. Additionally, Catalent has established an iPSC Center of Excellence in Düsseldorf, Germany, to advance iPSC process development.

In Depth

Key Findings

Catalent is strengthening its comprehensive CDMO manufacturing support and process development services for both autologous and allogeneic cell therapies. This includes support for CAR-T, T-cell receptor (TCR), tumor-infiltrating lymphocyte (TIL), NK cell, induced pluripotent stem cell (iPSC)-derived, and mesenchymal stem cell (MSC) therapies. The multi-product segregation suite at Catalent’s Princeton, U.S. site is designed with closed-system processing to minimize the risk of cross-contamination, ensuring cGMP compliance in line with FDA and EMA expectations. Furthermore, Catalent has established an iPSC Center of Excellence in Düsseldorf, Germany, specializing in iPSC process development.

Technical/Clinical Details

Autologous & Allogeneic Cell Therapy Manufacturing Capabilities: Catalent offers flexible manufacturing solutions for both autologous cell therapies, which use a patient’s own cells, and allogeneic cell therapies, which utilize cells from healthy donors for multiple patients. This capability is crucial for supporting the transition of various cell therapy modalities from clinical trials to commercial production. The closed-system workflow design ensures reproducibility and scalability, aiding critical process development activities such as media and cytokine reduction studies, process characterization, definition of acceptable ranges, and raw material quality assessment with supplier risk mitigation.
cGMP Compliance and Contamination Control: The design of the Princeton site emphasizes meeting stringent cGMP (current Good Manufacturing Practice) requirements. The multi-product segregation suites feature independent air handling systems and strict access controls to maximize product separation and contamination prevention. The adoption of closed-system processing is a key strategy for reducing manual exposure and minimizing the risk of microbial contamination.
Specialization in iPSC Process Development: The iPSC Center of Excellence in Düsseldorf, Germany, provides specialized expertise and technology to address the unique requirements of iPSC-derived cell products. This includes the development of closed-system workflows for end-to-end processing of human pluripotent stem cells (hPSC) from reprogramming to expansion, enhancing process efficiency, reducing variability through automation, and facilitating compliance with GMP standards. Closed-system designs, exemplified by Miltenyi Biotec’s CliniMACS Prodigy and MACSQuant Tyto Cartridge LC, offer reliable platforms for clinical-grade hPSC production, enabling safe and scalable applications in regenerative medicine, disease modeling, and cell therapy manufacturing.

Background & Context

The cell and gene therapy sector holds immense potential to revolutionize disease treatment, yet its manufacturing remains highly complex, demanding advanced technology and rigorous quality control. Challenges in scalability, high manufacturing costs, and stringent regulatory demands represent major barriers to delivering these therapies to patients. CDMOs like Catalent play an indispensable role in overcoming these challenges by providing specialized expertise and facilities, thereby supporting the rapid development and commercialization of innovative cell therapies.

Strategic Significance & Outlook

Catalent’s reinforcement of end-to-end services for autologous and allogeneic cell therapies and the establishment of its iPSC Center of Excellence are critically important for sustaining the growth of the cell therapy market. Specifically, the implementation of closed-system processing and automation technologies will improve manufacturing consistency and efficiency, reduce the cost of cell therapies, and ultimately enhance patient access. Demand for such comprehensive CDMO services is expected to grow significantly as the cell and gene therapy product pipeline matures and market launches accelerate.

Source: https://www.catalent.com/pharma/cell-gene-therapy/cell-therapy/development/autologous-allogeneic

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.